New schizophrenia drug passes early safety check
NCT ID NCT05406440
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Researchers monitored side effects and how many people stopped treatment due to problems. This is a first step to see if the drug might help control symptoms in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)
Glendale, California, 91206, United States
-
Collaborative Neuroscience Research, LLC ( Site 0004)
Garden Grove, California, 92845, United States
-
Hassman Research Institute Marlton Site ( Site 0003)
Marlton, New Jersey, 08053, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?